Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Phase 3positivedeucrictibant XRPositive
AI Analysis
Summary
Pharvaris announced positive topline results from the CHAPTER-3 Phase 3 pivotal study of deucrictibant XR for HAE prophylaxis, with primary and all secondary endpoints met. Marketing authorization applications are planned to be submitted in H1 2027.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Primary endpoint and all secondary efficacy endpoints met with statistical significance
Importance:8/10
Sentiment:
0.90
Phase 3 datapivotal studyHAEbradykinin B2 receptor antagonistoral therapyNDA submission planned
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on September 8, 2026 10:50 AM